Language: BG BG
← Back to results
Recruiting Not applicable NCT06546592

Locally Optimised Contouring With AI Technology for Radiotherapy

No applicable phase (e.g. observational)
Conditions: Contouring Segmentation Radiation Therapy Artificial Intelligence Deep Learning

Sponsor: Royal North Shore Hospital

trial.available_in: БГ
Overview
LOCATOR is a multicentre phase II randomised clinical trial that is looking at the process of contouring in radiation treatment for breast cancer patients. This study looks at whether contouring aided by artificial intelligence (AI) is comparable in quality to that of contouring done completely manually by a radiation oncologist. We are also looking at whether AI assisted contouring saves radiation oncologists time when compared to fully manual contouring. LOCATOR uses the LOCATOR software which is an in-house software developed locally and trained on local data.
Description
LOCATOR is a multicentre phase II non-inferiority randomised controlled trial looking at comparing AI assisted contours (with in-house LOCATOR software) against fully manual contouring in breast cancer patients. The primary endpoint is to show non inferiority in grade of AI assisted contouring when compared to fully manual contouring with a poor contour (score \<= 2) as per the MD Anderson Contouring Grade Scale. Secondary endpoints include geometric assessments of contour accuracy, dosimetric differences based on contours, performance (geometric) when compared to commercially available tools as well as economic cost-benefit analysis if in-house AI contouring tools. The study will randomise patients 3:1 to the intervention arm of LOCATOR assisted contours to manual contours. An initial AI contouring model for each tumor type will be trained on contours from 45 previous breast cases using a nnUNetv2 framework. The model will then be iteratively updated every 20-50 patients.
Who can participate
Inclusion Criteria: * 18 years and older who are planned for primary breast malignancy * ECOG performance 0-2 * Ability to understand and willingness to sign a written informed consent document * The target volume must be able to be objectively reviewed by current published national or international clinical guidelines Exclusion Criteria: * Patients under 18 years of age * Patients unable to understand consent documents
Locations 1
Australia (1)
Western Cancer Centre Dubbo
Dubbo , New South Wales
Technical details
Status
Recruiting
Phase
Not applicable
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
11.02.2025
Completion date
30.04.2030
Registry ID
NCT06546592
Source
anzctr
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.